# 1. Financial Performance ## A. Key Figures * **EBITDA:** **₹50 Cr** (–33% YoY) * PAT: ₹25 Cr (vs ₹29.3 Cr previous year) * **Adjusted EBITDA:** **₹14 Cr** (after one-time items) ## B. Revenue Decline * **Broad-Based Top-Line Pressure:** Revenue declined across all segments amid persistent market headwinds, signaling weak demand environment. ## C. EBITDA & PAT * **Profitability Erosion:** Sharp decline in EBITDA and PAT driven by higher employee costs and adverse operating leverage. * **Cost Inflation:** Employee expenses rose significantly due to **reversal of ESOP benefits**, **new hires at Lote and Dahej**, and annual increments. * **Offsetting Discipline:** Other expenses reduced by **₹5 Cr** through improved freight management and tighter operational controls. ## D. One-time Items * **Net One-Time Gain:** Financials include a **net gain of ₹36 Cr**, comprising a **₹7 Cr litigation settlement**, partially offset by **₹8 Cr labor code provision** and **₹9 Cr supply chain redesign costs**. ## E. Depreciation Change * **Accounting Policy Shift:** Laxmi transitioned from WDV to straight-line depreciation method post-industry benchmarking, with a measurable impact on reported earnings. --- # 2. Product & Segment Performance ## A. Key Figures * **Essentials Revenue:** **(6%) YoY decline** despite stable volumes * **Specialties Revenue:** **(30%) YoY decline** driven by price moderation, product mix shifts, and base effects * **Specialties EBITDA Margin:** **12–13%** in Q3 (down from 20–25%) * **Specialties Revenue (Historical):** Grew from **₹250 Cr (FY17)** to **~₹950 Cr (last FY)** * **Specialties Interim Revenue:** **₹560–570 Cr YTD**, with fluorination business targeted at **₹70–80 Cr** ## B. Essentials Segment Dynamics * **Resilient Domestic Demand:** Essentials volumes held firm with **70% domestic exposure**, insulating the business from global chemical downturns amid sustained India demand. * **Price-Driven Decline:** Revenue contraction attributed entirely to **lower acetic acid feedstock prices**, not demand weakness. * **Capacity Adequacy Questioned:** Investor inquiry raised on whether current capacity can support future volume growth amid margin pressure. ## C. Specialties Segment Challenges & Outlook * **Sharp Revenue & Margin Compression:** Significant decline driven by **price moderation**, **loss of one-time product**, and **exit of high-margin agro intermediate** (~10% of prior revenues). * **Structural Erosion:** Margin drop to 12–13% reflects the **disproportionate impact of phasing out a ~10%-revenue agro intermediate** with historically high profitability. * **Baseline Reset Underway:** Current-year performance reflects a new revenue baseline post-exit; long-term growth now hinges on newer streams like **fluorination (target: ₹70–80 Cr)**. --- # 3. Capacity & Production ## A. Key Figures * **Dahej Capex:** **₹710 Cr** (65% allocated to Specialties) * **Lote Facility Capacity:** **70,000 tons** ethyl acetate (world-scale, under development) ## B. Dahej Expansion * **Phased Ramp-Up Underway:** Phase 1 is operational with customer supply live under a multiyear take-or-pay contract, while Phase 2 remains on track for mechanical completion by end-Q4. * **Strategic Scale & Timing:** The Dahej expansion, the company’s largest capex project, will see full production ramp-up extend into FY '27 and FY '28, supporting long-term specialty chemicals growth. ## C. Lote Facility Ramp-up * **Fluoro Intermediates Onstream:** Operations are progressing as planned and linked to the fluorination specialty portfolio, with first-year performance targets unchanged. * **Growth Pipeline:** A new world-scale ethyl acetate unit is under active development at Lote, expanding downstream integration and volume potential. ## D. Mahad Utilization * **High Utilization & Flexibility:** Ketene and diketene operations at Mahad remain robust, supported by asset flexibility now being replicated at Dahej. * **Product Transition Executed Locally:** Replacement production for the phased-out intermediate has been successfully routed to Mahad, leveraging pre-established capabilities. ## E. Capex Allocation * **Specialties-Focused Investment:** The majority of Dahej capex is directed toward diketene and derivatives, reinforcing strategic emphasis on high-value specialty segments. * **Capacity Drivers Confirmed:** High utilization across both Essentials and Specialties platforms underpinned the decision to expand production footprint. --- # 4. Demand & Pricing Trends ## A. Key Figures * **Feedstock Prices:** **Double-digit declines** across acetic acid and aromatics value chains ## B. Acetic Acid Pricing Dynamics * **Pricing Recovery Underway:** Acetic acid prices rebounded sharply from unsustainable lows, supported by capacity cuts in **China and ASEAN**, signaling a bottoming out of the cycle. * **Stable Equilibrium Expected:** Post-Chinese New Year capacity restarts unlikely to retest prior lows; a new price floor is forming in the **$330–$380** range. ## C. Ethyl Acetate Spreads & Product Strategy * **Spreads Remain Pressured:** Ethyl acetate margins in Essentials stayed weak despite raw material relief, with strategy pivoting to **volume-driven profitable growth** across segments. ## D. End-market Demand Trends * **Core End-markets Stable:** Packaging, inks, adhesives, and pharma show **stable QoQ demand**, providing solid foundation for new capacity absorption. * **Mixed Signals in Key Verticals:** Agrochemicals demand steady, while paints & coatings remain **weak to moderate**, reflecting global customer exposure. ## E. Feedstock Cost Environment * **Deflation Boosts Specialties:** Significant feedstock cost moderation has enhanced profitability in the Specialties segment, though recent rebounds warrant caution. * **Cautious Outlook on Sustainability:** Early signs of raw material price recovery observed, but trajectory remains uncertain and will be assessed incrementally. --- # 5. Strategic Initiatives ## A. Self-help Measures * **Sustained Operational Focus:** Ongoing emphasis on productivity gains, cost discipline, and execution excellence underpins long-term value creation. * **Growth Project Prioritization:** Strategic allocation of resources toward new growth initiatives and specialty product development to drive vertical expansion. ## B. Replacement Product Launch * **Product Transition Underway:** Replacement for phased-out agro intermediate in qualification phase, with **sales launch expected in Q4** and ramp-up through FY '27. ## C. Customer Proximity Push * **Market-Centric Capacity Expansion:** New capacities launching in Q4 and next fiscal year will be supported by closer customer engagement to accelerate market penetration. ## D. Global Capacity Build * **Diketene Derivatives Leadership:** Firm right to win globally, with Mahad and Dahej facilities set to scale production through 2027 and into 2028. * **Expansion on Track:** Global capacity build progressing on time and within budget across segments, including fluorination project. --- # 6. Risks & Industry Factors ## A. Key Figures * **B. S. Revenue Exposure:** **INR 300 Cr** (10% of top line) · **INR 30 Cr** directly impacted by tariffs * **Acetic Acid Price Range:** **$320–$330** * **India-EU Tariff Disparity:** **13%** avg. import duty on EU goods vs. **22%** on Indian exports to EU ## B. Product Mix Pressure * **Margin Headwinds:** Performance pressured by **weakness in ethyl acetates**, a **shift away from higher-margin Specialties**, and **incremental costs from Lote and Dahej ramp-up**. ## C. Global Oversupply * **Challenging Macro Backdrop:** Global chemical markets remain oversupplied, with structural adjustments underway via asset closures and restructuring, particularly in Europe and China. * **Regional Competitiveness Shifts:** European exports to India constrained by **uncompetitive energy costs**, limiting exposure; imports expected only for **proprietary or super-specialty chemicals**. * **Supply-Demand Imbalance:** Acetic acid market remains **structurally long**, with prices near **cash-cost levels**, signaling sustained pressure across the cost curve. * **India’s Import Dependence:** Remains a net importer of key intermediates like **propylene oxide, MDI, and TDI**, though specialty value chains still favor European producers. ## D. Tariff Impacts * **Limited U.S. Tariff Impact:** Direct financial exposure minimal; **indirect effects possible** via customers facing U.S. market headwinds. * **FTA as Growth Catalyst:** India-EU FTA expected to be **net positive**, supported by existing tariff asymmetry favoring Indian exporters. * **No China Trade Rebate Link:** Recent acetic acid price moves unrelated to Chinese agro-product rebates, clarifying market misconceptions. --- # 7. Guidance & Outlook ## A. Key Figures * **Fluorochem Revenue Target:** **₹80 Cr** expected by FY '26 ## B. H2 FY '27 Revenue * **Diketene Expansion Timing:** Revenue contribution expected in H2 FY '27, pending successful customer qualifications. ## C. FY '26 Fluorochem Target * **On-Track Execution:** Fluorochem project progressing as planned, with first 9 months' performance supporting full-year revenue target.